Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Patients with multiple sclerosis (MS) are eligible for the study if they meet the following criteria:~1. Relapsing recurrent MS with an evolution of at last 6 months before the study began.~2. Both males and females, aged 20 - 65 years~3. Neurologic Expanded Disability Status Scale (EDSS) 3 - 7~4. Who are in first-line immunomodulatory therapy and have a stable disease~5. No more than one outbreak per year.~6. The absence of antiepileptic antecedent and electroencephalogram without epileptic activity.~7. For females: postmenopausal or surgically sterile, or using an acceptable method of birth control~Exclusion Criteria:~1. History of cardiovascular disease (syncope, arrhythmia, or myocardial infarction within the last two years), systolic blood pressure greater than 150 or less than 70 mm Hg, diastolic blood pressure greater than 110 or less than 50 mm Hg, or heart rate greater than 110 or less than 50 beats/minute; impaired hepatic function (total hepatic enzyme or bilirubin levels greater than 2 times the upper limits of normal) or impaired renal function (creatinine level greater than 2 times the upper limits of normal) less than 6 months before the study~2. Known allergy to pyridine-containing drugs~3. Neurologic, degenerative, or psychiatric disorders that would impair the patient's ability to complete the protocol~4. Any illness or abnormality that would jeopardize patient safety or interfere with the conduct of the study~5. History of substance abuse~6. Inability to discontinue excluded concomitant drug therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 4-aminopyridine treatment (Type: ACTIVE_COMPARATOR): 4-aminopyridine is given as gelatin capsules containing 4-aminopyridine 10 mg and microcrystalline cellulose as the excipient. Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
- Placebo (Type: PLACEBO_COMPARATOR): Patients randomized to the placebo sequence will receive placebo for 20 weeks after the run-in period. They will be blinded to the fact that they are taking placebo, and capsules will be identical in appearance to the intervention capsules.

Based on this trial design, predict the completion outcome and termination type (if applicable).